Drug Trial Radar · NCT04940039
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Jul 22, 2021
Primary completion
Apr 16, 2024
Study completion Apr 16, 2024
Sponsor
- Lead sponsor
- Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 34 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term symptomatic response (Visit 2 \[Week 1\] to Visit 14/Week 66 \[End of Study {EOS}\]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month \[PP1M\] and 3-month \[PP3M\] formulations).
Conditions
- Schizophrenia
Interventions
Risperidone 3 mgDrug
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Paliperidone Palmitate 50 mg eq.Drug
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Paliperidone Palmitate 75 mg eq.Drug
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 100 mg eq.Drug
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 150 mg eq.Drug
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 175 mg eq.Drug
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 263 mg eq.Drug
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 350 mg eq.Drug
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 525 mg eq.Drug
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University Teaching Hospital of Butare(CHUB)
Butare, Rwanda
Kibuye Referral Hospital
Kibuye, Rwanda
CARAES Ndera Neuro-Psychiatric Hospital
Kigali, Rwanda
University Teaching Hospital of Kigali
Kigali, Rwanda
Rwamagana Provincial Hospital
Rwamagana, Rwanda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.